ANI Pharmaceuticals (ANIP) announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic version of the reference listed drug, or RLD, Alinia. U.S. annual sales for Nitazoxanide Tablets total approximately $36.1M, based on December 2024 moving annual total IQVIA data.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals announces royalty obligation buyout for Iluvien, Yutiq
- Positive Outlook for ANI Pharmaceuticals: FDA Approval and Strategic Moves Drive Buy Rating
- ANI Pharmaceuticals announces FDA approval for expansion of Iluvien label
- ANI Pharmaceuticals initiated with a Buy at Jefferies
- ANI Pharmaceuticals initiated with an Overweight at JPMorgan